journal article·2024-09Open access

Primary and Orthotopic Murine Models of Nasopharyngeal Carcinoma Reveal Molecular Mechanisms Underlying its Malignant Progression

Xudong Wan, Yuantao Liu, Yiman Peng, Jian Wang, Shu‐mei Yan, Lu Zhang, Wanchun Wu, Lei Zhao, Xuelan Chen, Kexin Ren, Haicheng Long, Yiling Luo, Qin Yan, Lele Zhang, Dengzhi Lei, Pengpeng Liu, Shujun Li, Lihui Liu, Linjie Guo, Jiajia Du, Mengsha Zhang, Siqi Dai, Yi Yang, Hongyu Liu, Nianyong Chen, Jinxin Bei, Lin Feng, Yu Liu, Mu‐sheng Zeng, Chong Chen, Qian Zhong

Advanced Science· Volume 11· Issue 36

Abstract

Abstract Nasopharyngeal carcinoma (NPC), a squamous cell carcinoma originating in the nasopharynx, is a leading malignancy in south China and other south and east Asia areas. It is frequently associated with Epstein‐Barr virus (EBV) infection, while there are also some NPC patients without EBV infection. Here, it is shown that the EBV+ (EBV positive) and EBV‐ (EBV negative) NPCs contain both shared and distinct genetic abnormalities, among the latter are increased mutations in TP53 . To investigate the functional roles of NPC‐associated genetic alterations, primary, orthotopic, and genetically defined NPC models were developed in mice, a key tool missed in the field. These models, initiated with gene‐edited organoids of normal nasopharyngeal epithelium, faithfully recapitulated the pathological features of human disease. With these models, it is found that Trp53 and Cdkn2a deficiency are crucial for NPC initiation and progression. And latent membrane protein1 (LMP1), an EBV‐coding oncoprotein, significantly promoted the distal metastasis. Further, loss of TGFBR2 , which is frequently disrupted both in EBV‐ and EBV+ NPCs, dramatically accelerated the progression and lung metastasis of NPC probably by altering tumor microenvironment. Taken together, this work establishes a platform to dissect the genetic mechanisms underlying NPC pathogenesis and might be of value for future translational studies.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA modifications and cancer · Cancer Research and Treatments · interferon and immune responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Division of Thoracic Tumor Multimodality Treatment State Key Laboratory of Biotherapy and Cancer Center West China Hospital Sichuan University Chengdu Sichuan 610041 China

State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Department of Experimental Research Sun Yat‐sen University Cancer Center Sun Yat‐sen University Guangzhou Guangdong 510060 China

Department of Otolaryngology West China Hospital Sichuan University Chengdu Sichuan 610041 China

Department of Hematology West China Hospital Sichuan University Chengdu Sichuan 610041 China

Department of Gastroenterology West China Hospital Sichuan University Chengdu Sichuan 610041 China

Department of Biotherapy State Key Laboratory of Biotherapy and Cancer Center West China Hospital Sichuan University Chengdu Sichuan 610041 China

Frontiers Medical Center Tianfu Jincheng Laboratory Chengdu Sichuan 610212 China

Funding

National Natural Science Foundation of China · Guangdong Provincial Department of Science and Technology

References (59)

Show source-provided references
1. 10.1016/S0140-6736(19)30956-010.1016/S0140-6736(19)30956-0 ↗
2. 10.18632/oncotarget.768810.18632/oncotarget.7688 ↗
3. 10.1200/JCO.2015.60.934710.1200/JCO.2015.60.9347 ↗
4. 10.1093/annonc/mdu50710.1093/annonc/mdu507 ↗
5. 10.1007/s12250-015-3592-510.1007/s12250-015-3592-5 ↗
6. 10.1016/j.semcancer.2011.12.01110.1016/j.semcancer.2011.12.011 ↗
7. 10.1038/ng.300610.1038/ng.3006 ↗
8. 10.1038/s41467-021-24348-610.1038/s41467-021-24348-6 ↗
9. 10.1073/pnas.160760611310.1073/pnas.1607606113 ↗
10. 10.1158/0008-5472.CAN-05-064810.1158/0008-5472.CAN-05-0648 ↗
11. 10.1016/S0046-8177(00)80216-610.1016/S0046-8177(00)80216-6 ↗
12. 10.1016/S0304-3835(98)00209-210.1016/S0304-3835(98)00209-2 ↗
13. 10.1038/sj.bjc.669081810.1038/sj.bjc.6690818 ↗
14. 10.1146/annurev-pathmechdis-012418-01302310.1146/annurev-pathmechdis-012418-013023 ↗
15. 10.1136/jitc-2020-00158810.1136/jitc-2020-001588 ↗
16. 10.3390/jcm1204158810.3390/jcm12041588 ↗
17. Chang Y.‐S. · Cancer Res. · 1989 · 49 · 6752
18. 10.1038/s41467-018-06889-510.1038/s41467-018-06889-5 ↗
19. 10.3390/cancers1204102510.3390/cancers12041025 ↗
20. 10.1038/s41467-021-23379-310.1038/s41467-021-23379-3 ↗
21. 10.1038/s43018-022-00361-610.1038/s43018-022-00361-6 ↗
22. 10.1016/j.celrep.2022.11148210.1016/j.celrep.2022.111482 ↗
23. 10.1016/j.ccell.2022.08.01010.1016/j.ccell.2022.08.010 ↗
24. 10.1002/advs.20230038310.1002/advs.202300383 ↗
25. 10.1038/ncomms1412110.1038/ncomms14121 ↗
26. 10.1016/0140-6736(90)90206-K10.1016/0140-6736(90)90206-K ↗
27. Ali M. · J. Anat. · 1965 · 99 · 657
28. 10.1159/00014623510.1159/000146235 ↗
29. 10.1158/1055-9965.EPI-06-045510.1158/1055-9965.EPI-06-0455 ↗
30. 10.1002/path.248710.1002/path.2487 ↗
31. 10.18632/oncotarget.405710.18632/oncotarget.4057 ↗
32. 10.3390/ijms13101373710.3390/ijms131013737 ↗
33. 10.1002/ijc.291012020210.1002/ijc.2910120202 ↗
34. 10.1002/jmv.2110210.1002/jmv.21102 ↗
35. 10.1038/sj.cr.729016310.1038/sj.cr.7290163 ↗
36. 10.1002/cam4.250610.1002/cam4.2506 ↗
37. 10.1158/1078-0432.CCR-08-019810.1158/1078-0432.CCR-08-0198 ↗
38. 10.1158/0008-5472.CAN-09-046810.1158/0008-5472.CAN-09-0468 ↗
39. 10.1016/j.canlet.2013.05.01810.1016/j.canlet.2013.05.018 ↗
40. 10.1016/S1044579X0200090110.1016/S1044579X02000901 ↗
41. 10.1016/j.cell.2011.12.03110.1016/j.cell.2011.12.031 ↗
42. 10.1182/blood-2013-04-49900410.1182/blood-2013-04-499004 ↗
43. 10.1186/s13045-016-0341-710.1186/s13045-016-0341-7 ↗
44. 10.1128/jvi.63.6.2469-2475.198910.1128/jvi.63.6.2469-2475.1989 ↗
45. 10.1371/journal.pone.006074310.1371/journal.pone.0060743 ↗
46. 10.4161/cc.2892110.4161/cc.28921 ↗
47. 10.1158/1541-7786.MCR-17-013410.1158/1541-7786.MCR-17-0134 ↗
48. 10.1038/nbt.383610.1038/nbt.3836 ↗
49. 10.1038/nbt.383710.1038/nbt.3837 ↗
50. 10.1073/pnas.190471411610.1073/pnas.1904714116 ↗
51. 10.1016/j.gde.2012.01.00410.1016/j.gde.2012.01.004 ↗
52. 10.15252/emmm.20160685710.15252/emmm.201606857 ↗
53. 10.1158/1078-0432.CCR-07-008910.1158/1078-0432.CCR-07-0089 ↗
54. 10.1016/j.ijrobp.2010.03.02410.1016/j.ijrobp.2010.03.024 ↗
55. 10.1158/2159-8290.CD-11-010010.1158/2159-8290.CD-11-0100 ↗
56. 10.1016/j.stem.2020.04.00310.1016/j.stem.2020.04.003 ↗
57. 10.1038/nature2549210.1038/nature25492 ↗
58. 10.1016/j.cell.2022.02.01510.1016/j.cell.2022.02.015 ↗
59. 10.1038/nature1715710.1038/nature17157 ↗